Recently, in a comprehensive analysis of tumor grafts derived from head and neck tumor patients, dasatanib displayed in vivo efficacy when combined with the JAK2 inhibitor BMS911543 in tumor-bearing mice [51]. Here, JAK2 is linked to head and neck neoplasm.